Effects of an elemental diet, Elental®, may differ between healthy oral cells and oral cancer cells

Harada,Koji; Ferdous,Tarannum; Watanabe,Kenji; Mizukami,Yoichi; Mishima,Katsuaki

doi:10.3892/or.2020.7896

Effects of an elemental diet, Elental®, may differ between healthy oral cells and oral cancer cells

Authors:
- Koji Harada
- Tarannum Ferdous
- Kenji Watanabe
- Yoichi Mizukami
- Katsuaki Mishima
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755‑8505, Japan, Center for Gene Research, Science Research Center, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan
Published online on: December 11, 2020 https://doi.org/10.3892/or.2020.7896
Pages: 738-751

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effectiveness of an elemental diet (ED), Elental®, against radiotherapy‑ or chemoradiotherapy‑induced oral mucositis was previously reported. However, the administration of additional nutrition or an ED in patients with oral cancer may also provide extra nutrition for cancer cells, which could result in cancer development. At present, it remains unclear whether the beneficial effects of an ED are likely to surpass its potential harmful effects on oral cancer treatment. In the present study, we aimed to clarify whether Elental® has different effects on a healthy human oral keratinocyte (HOK) cell line compared with its effects on oral squamous cell carcinoma (OSCC) cell lines (HSC2, HSC3, HSC4). The efficacy of Elental® was compared in relation to the growth and migration ability of HOK and OSCC cell lines using MTT assay and migration assay, respectively. In addition, whole transcriptome analysis and network analysis were performed to determine the difference in the mechanism of action of Elental® between HOK and HSC2 cells. In addition, Elental® promoted growth and migration ability of‑malnourished and 5‑fluorouracil (5‑FU)‑treated damaged HOK cells cultured in low nutrition medium (0% growth supplement). However, Elental® did not affect the growth ability of 5‑FU‑treated damaged HSC2 cell line in low nutrition medium (0 or 1% fetal bovine serum (FBS), as well as the growth ability of HSC3 and HSC4 cell lines in medium containing 0% FBS. Elental® pre‑treatment also enhanced the apoptosis‑inducing effect of anticancer agents against OSCC cells. In addition, whole transcriptome analysis and Ingenuity Pathways Analysis (IPA) data suggested that Elental® may help in the proliferation and survival of HOK through the induction of ERK. Moreover, Elental® added stress to HSC2 cells through the induction of the endoplasmic reticulum stress response marker, BiP and GRP 94. The results showed that Elental® may add stress to HSC2 cells and provide growth stimulation to HOK. These findings suggest that the effects of Elental® on healthy oral cells and oral cancer cells may differ.

View Figures

View References

1	Duncan M and Grant G: Oral and intestinal mucositis-causes and possible treatments. Aliment Pharmacol Ther. 18:853–874. 2003. View Article : Google Scholar : PubMed/NCBI
2	Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E and Gudkov AV: Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: Implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys. 83:228–234. 2012. View Article : Google Scholar : PubMed/NCBI
3	Sonis ST: Oral mucositis. Anticancer Drugs. 22:607–612. 2011. View Article : Google Scholar : PubMed/NCBI
4	McCarthy GM, Awde JD, Ghandi H, Vincent M and Kocha WI: Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol. 34:484–490. 1998. View Article : Google Scholar : PubMed/NCBI
5	Miyano K, Ueno T, Yatsuoka W and Uezono Y: Treatment for cancer patients with oral mucositis: Assessment based on the mucositis study group of the multinational association of supportive care in cancer in international society of oral oncology (MASCC/ISOO) in 2013 and proposal of possible novel treatment with a Japanese herbal medicine. Curr Pharm Des. 22:2270–2278. 2016. View Article : Google Scholar : PubMed/NCBI
6	Lalla RV, Sonis ST and Peterson DE: Management of oral mucositis in patients who have cancer. Dent Clin North Am. 52:61–77. 2008. View Article : Google Scholar : PubMed/NCBI
7	Skubitz KM: Glutamine as a potential treatment for the prevention of chemotherapy induced mucositis. J Infusional Chemotherapy. 4:64–67. 1994.
8	Kyllo RL and Anadkat MJ: Dermatologic adverse events to chemotherapeutic agents, part 1: Cytotoxics, epidermal growth factor receptors, multikinase inhibitors, and proteasome inhibitors. Semin Cutan Med Surg. 33:28–39. 2014. View Article : Google Scholar : PubMed/NCBI
9	Shou J, Lieberman MD, Hofmann K, Leon P, Redmond HP, Davies H and Daly JM: Dietary manipulation of methotrexate-induced enterocolitis. JPEN J Parenter Enteral Nutr. 15:307–312. 1991. View Article : Google Scholar : PubMed/NCBI
10	Campos MI, Campos CN, Aarestrup FM and Aarestrup BJ: Oral mucositis in cancer treatment: Natural history, prevention and treatment. Mol Clin Oncol. 2:337–340. 2014. View Article : Google Scholar : PubMed/NCBI
11	Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE, et al: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 109:820–831. 2007. View Article : Google Scholar : PubMed/NCBI
12	Peterson DE, Bensadoun RJ and Roila F; ESMO Guidelines Working Group, : Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol. 20 (Suppl 4):S174–S177. 2009. View Article : Google Scholar
13	Quinn B, Potting CM, Stone R, Blijlevens NM, Fliedner M, Margulies A and Sharp L: Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer. 44:61–72. 2008. View Article : Google Scholar : PubMed/NCBI
14	Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L, Salzwimmer M, Lizambri R, Emmerson L, Chen MG and Berger D: Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: A randomized, placebo-controlled trial. J Clin Oncol. 29:2815–2820. 2011. View Article : Google Scholar : PubMed/NCBI
15	Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R, et al: NCCN Task force report. Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 6 (Suppl 1):S1–S21; quiz S22-S24. 2008. View Article : Google Scholar : PubMed/NCBI
16	Svanberg A, Ohrn K and Birgegard G: Oral cryotherapy reduces mucositis and improves nutrition-a randomised controlled trial. J Clin Nurs. 19:2146–2151. 2010. View Article : Google Scholar : PubMed/NCBI
17	Scully C, Epstein J and Sonis S: Oral mucositis: A challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head Neck. 26:77–84. 2004. View Article : Google Scholar : PubMed/NCBI
18	Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C and Franquin JC: Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. Int J Radiat Oncol Biol Phys. 38:697–703. 1997. View Article : Google Scholar : PubMed/NCBI
19	Online EA Pharma Co., Ltd. Products Information, Elental®, . simplehttp://www.eapharma.co.jp/medicalexpert/product/elental/elental_information.htmlWebpage in Japanese. July 25–2019
20	Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T and Matsumoto K: Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: Cytokine production and endoscopic and histological findings. Inflamm Bowel Dis. 11:580–588. 2005. View Article : Google Scholar : PubMed/NCBI
21	Johtatsu T, Andoh A, Kurihara M, Iwakawa H, Tsujikawa T, Kashiwagi A, Fujiyama Y and Sasaki M: Serum concentrations of trace elements in patients with Crohn's disease receiving enteral nutrition. J Clin Biochem Nutr. 4:197–201. 2007. View Article : Google Scholar
22	Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S and Matsumoto K: Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: A prospective study. Inflamm Bowel Dis. 13:1493–1501. 2007. View Article : Google Scholar : PubMed/NCBI
23	Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, Tanaka T, Maruyama Y, Ikeya K, Sugimoto K, et al: Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. Dig Liver Dis. 44:649–654. 2012. View Article : Google Scholar : PubMed/NCBI
24	Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T and Matsumoto K: Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: A prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 25:67–72. 2007. View Article : Google Scholar : PubMed/NCBI
25	Fukui T, Itoh Y, Orihara M, Yoshizawa K, Takeda H, Kawada S and Yoshioka T: Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer. Gan To Kagaku Ryoho. 38:2597–2601. 2011.(In Japanese). PubMed/NCBI
26	Ogata Y, Takeuchi M, Ishibashi N, Kibe S, Takahashi K, Uchida S, Murakami N, Yahara T and Shirouzu K: Efficacy of Elental on prevention for chemotherapy-induced oral mucositis in colorectal cancer patients. Gan To Kagaku Ryoho. 39:583–587. 2012.(In Japanese). PubMed/NCBI
27	Harada K, Minami H, Ferdous T, Kato Y, Umeda H, Horinaga D, Uchida K, Park SC, Hanazawa H, Takahashi S, et al: The Elental^® elemental diet for chemoradiotherapy-induced oral mucositis: A prospective study in patients with oral squamous cell carcinoma. Mol Clin Oncol. 10:159–167. 2019.PubMed/NCBI
28	Harada K, Ferdous T, Horinaga D, Uchida K, Mano T, Mishima K, Park S, Hanazawa H, Takahashi S, Okita A, et al: Efficacy of elemental diet on prevention for chemoradiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma. Support Care Cancer. 24:953–959. 2016. View Article : Google Scholar : PubMed/NCBI
29	Harada K, Ferdous T, Kobayashi H and Ueyama Y: Elemental diet accelerates the recovery from oral mucositis and dermatitis induced by 5-Fluorouracil through the induction of fibroblast growth factor 2. Integr Cancer Ther. 17:423–430. 2018. View Article : Google Scholar : PubMed/NCBI
30	Harada K, Ferdous T, Mizukami Y and Mishima K: Elemental diet inhibits pro-inflammatory cytokine production in keratinocytes through the suppression of NF-κB activation. Oncol Rep. 40:361–368. 2018.PubMed/NCBI
31	Luo M, Brooks M and Wicha MS: Asparagine and Glutamine: Co-conspirators fueling metastasis. Cell Metab. 27:947–949. 2018. View Article : Google Scholar : PubMed/NCBI
32	Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, et al: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554:378–381. 2018. View Article : Google Scholar : PubMed/NCBI
33	Liu H, Ling W, Shen ZY, Jin X and Cao H: Clinical application of immune-enhanced enteral nutrition in patients with advanced gastric cancer after total gastrectomy. J Dig Dis. 13:401–406. 2012. View Article : Google Scholar : PubMed/NCBI
34	ASPEN Board of Directors and the Clinical Guidelines Task Force, . Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr. 26 (Suppl 1):1SA–138SA. 2002. View Article : Google Scholar : PubMed/NCBI